AOD-9604 research guide for Mon. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't found on pharmacy shelves in Mon or anywhere else for that matter — it's a research-grade peptide available through a dedicated online market. The upside of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers more rigorous quality data than any local market ever offers. Separating properly characterised AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Mon researchers the framework to verify sourcing options methodically and source verified-quality AOD-9604 with confidence.
The Science Behind AOD-9604
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Mon researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
AOD-9604 Purchasing Guide
Before evaluating any specific vendor, establish a quality benchmark — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. Signs of a credible vendor beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. The powdered lyophilised form of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations degrade within weeks even when refrigerated.
Order AOD-9604 — ships to Mon
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is for educational purposes only. Proper handling of AOD-9604 requires sterile reconstitution technique — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and temperature control throughout the entire workflow. Quality AOD-9604 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that verified-quality sourcing directly prevents. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
